|Bid||14.01 x 3000|
|Ask||14.02 x 3100|
|Day's range||13.93 - 14.04|
|52-week range||13.91 - 19.97|
|Beta (5Y monthly)||1.10|
|PE ratio (TTM)||11.70|
|Forward dividend & yield||0.84 (5.94%)|
|Ex-dividend date||30 Mar 2021|
|1y target est||N/A|
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval.
Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.